+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

S

Actively Recruiting

This research study focuses on evaluating the safety and performance of Clareon TruPlus Monofocal Intraocular Lenses IOLs, which are implanted during cataract surgery to restore clear vision after the cloudy natural lens is removed. The lenses are intended to stay in the eyes for the patients lifetime. The study targets adults diagnosed with aphakia and astigmatism who are undergoing cataract surgery. Participants will receive Clareon TruPlus Monofocal IOLs, either Non-Toric or Toric, implanted using a phacoemulsification procedure. The choice of lens type depends on the individuals astigmatism and surgeon recommendation. The study includes one preoperative visit, two surgical visitsincluding second eye surgery within 0 to 14 days after the firstand five postoperative visits over approximately 13 months. During the trial, participants will be monitored through eight study visits with assessments including vision quality checks using the Mean Binocular Photopic Best Corrected Distance Visual Acuity at baseline and at 1, 3, and 12 months after surgery. The study tracks how well the lenses perform and their safety over time, supporting long-term observation after lens implantation.

Age: 22Years +All GendersPhase Not Applicable
5 locations
E

Actively Recruiting

This research aims to evaluate the rate of malposition and related clinical outcomes of the Hydrus Microstent implant in patients with primary open-angle glaucoma undergoing cataract surgery. The study focuses on patients with age-related cataracts and glaucoma managed with up to four topical medications, assessing device placement and safety over a 24-month period after surgery. Participants will undergo cataract surgery with placement of a monofocal intraocular lens followed immediately by implantation of the Hydrus Microstent device. The Hydrus Microstent is a crescent-shaped implant designed to create a pathway for fluid drainage in the eye. The study is a single-group, non-randomized clinical trial where all participants receive this combined treatment. During the study, participants will attend a screening visit, the surgery day, and eight post-operative visits scheduled from Day 1 through Month 24 to monitor device position and associated clinical effects. Researchers will track adverse events during surgery and post-operation and measure the rate of significant device malposition linked to clinical outcomes. The study is sponsored by Alcon Research and lasts up to 24 months post-surgery.

Age: 45Years +All GendersPhase Not Applicable
22 locations
M

Actively Recruiting

Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.

Age: 18Years +All Genders
2393 locations